Clare Bradley, Simon G. Ashwell, James W. Stephens, Elke Witthaus and Philip D. Home (2008) Treatment satisfaction and quality of life with insulin glargine plus insulin lispro compared with NPH insulin plus unmodified human insulin in people with Type 1 diabetes. Diabetes Care, 31 (6). pp. 1112-1117 . ISSN 0149-5992
Full text access: Open
OBJECTIVE— The purpose of this study was to compare quality of life and treatment satisfaction using insulin glargine plus insulin lispro with that using NPH insulin plus unmodified human insulin in adults with type 1 diabetes managed with multiple injection regimens. RESEARCH DESIGN AND METHODS— As part of a 32-week, five-center, two-way crossover study in 56 individuals with type 1 diabetes randomized to evening insulin glargine plus mealtime insulin lispro or to NPH insulin (once or twice daily) plus mealtime unmodified human insulin, the Diabetes Treatment Satisfaction Questionnaire (DTSQ) and the Audit of Diabetes Dependent Quality of Life questionnaire were completed at baseline and at weeks 16 and 32, with additional interim DTSQ measurements. RESULTS— For all patients combined, the mean baseline present QoL score was 1.3, reflecting “good” QoL. Present QoL improved with glargine lispro but did not change with NPH human insulin (1.6 0.1 [mean SEM] vs. 1.3 0.1, difference 0.3 [95% CI 0.1– 0.6]; P 0.014). Baseline mean average weighted impact score (AWI) of diabetes on QoL was 1.8, indicating a negative impact of diabetes on QoL. The AWI score at end point improved significantly with glargine lispro but changed little with NPH human insulin (1.4 0.1 vs. 1.7 0.1, 0.3 [0.0–0.6]; P 0.033). Treatment satisfaction (DTSQ 36-0 scale score) at end point was markedly greater with glargine plus lispro compared with that for NPH plus human insulin (32.2 3.4 vs. 23.9 7.2, 8.6 [6.5–10.6]; P 0.001). CONCLUSIONS— Insulin glargine plus insulin lispro improves treatment satisfaction, reduces the negative impact of diabetes on QoL, and improves QoL in comparison with NPH insulin plus unmodified human insulin in type 1 diabetes.
This is a Draft version This version's date is: 06/2008 This item is peer reviewed
https://repository.royalholloway.ac.uk/items/cfa4257d-eaa9-6492-f9f8-6e224761c664/1/
Deposited by Al Dean (ZSRA118) on 17-Mar-2010 in Royal Holloway Research Online.Last modified on 19-May-2011
(C) 2008 American Diabetes Association, whose permission to mount this version for private study and research is acknowledged. The repository version is the author's final draft.
1.Speight J, Bradley C: DAFNE: improved quality of life as a result of intensified treatment is counter-intuitive to many clinicians [article online], 2002. Available from http://bmj.com/cgi/eletters/325/7367/746#26769. Accessed 15 April 2008
2.Bradley C, Pierce MB, Hendrieckx C, Riazi A, Barendse S: Diabetes mellitus. In Health Psychology. Johnston M, Johnston DW, Eds. [Vol. 8 in Comprehensive Clinical Psychology. Bellack AS, Hersen M, Eds.] Oxford, U.K., Elsevier Science, 1998, p. 277-304
3.Howorka K: Preface. In Functional Insulin Treatment, 2nd ed. Berlin, Springer Verlag; Authors preface. 1996
4.Witthaus E, Stewart J, Bradley C: Treatment satisfaction and psychological well-being with insulin glargine compared with NPH in patients with type 1 diabetes. Diabet Med 18: 619-626, 2001CrossRefMedlineWeb of Science
5.Ahmed A, Home P: Optimal provision of daytime NPH insulin in patients using the insulin analog lispro. Diabetes Care 21:1707-1713, 1998Abstract
6.Ciofetta M, Lalli C, Del Sindaco P, Torlone E, Pampanelli S, Mauro L, Chiara DL, Brunetti P, Bolli GB: Contribution of postprandial versus interprandial blood glucose to HbA1c in type 1 diabetes on physiologic intensive therapy with lispro insulin at mealtime. Diabetes Care 22:795-800, 1999Abstract/FREE Full Text
7.Lalli C, Ciofetta M, Del Sindaco P, Torlone E, Pampanelli S, Compagnucci P, Bartocci L, Brunetti P, Bolli GB: Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime. Diabetes Care 22:568-477, 1999
8.Ashwell SG, Amiel SA, Bilous RW, Dashora U, Heller SR, Hepburn DA, Shutler SD, Stephens JW, Home PD: Improved glycaemic control with insulin glargine plus insulin lispro. Diabet Med 23:285-292, 2006CrossRefMedlineWeb of Science
9.Porcellati F, Rossetti P, Pampanelli S, Fanelli CG, Torlone E, Scionti L, Perriello G, Bolli GB: Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with type 1 diabetes mellitus given meal-time lispro insulin. Diabet Med 21:1213-1220, 2004CrossRefMedlineWeb of Science
10.Rossetti P, Pampanelli S, Fanelli C, Porcellati F, Costa E, Torlone E, Scionti L, Bolli GB: Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime. Diabetes Care 26:1490-1496, 2003Abstract/FREE Full Text
11.Home PD, Lindholm A, Riis A: Insulin aspart vs. human insulin in the management of long-term blood glucose control in type 1 diabetes mellitus: a randomized controlled trial. Diabet Med 17:762-770, 2000CrossRefMedlineWeb of Science
12.DeVries JH, Lindholm A, Jacobsen JL, Heine RJ, Home PD: A randomized trial of insulin aspart with intensified basal NPH insulin supplementation in people with type 1. Diabet Med 20:312-318, 2003Medline
13.Bott U, Ebrahim S, Hirschberger S, Skovlund SE: Effect of the rapid-acting insulin analogue insulin aspart on quality of life and treatment satisfaction in patients with type 1 diabetes. Diabet Med 20:626-634, 2003CrossRefMedlineWeb of Science
14.Howorka K, Pumprla J, Schlusche C, Wagner-Nosiska D, Schabmann A, Bradley C: Dealing with ceiling baseline treatment satisfaction level in patients with diabetes under flexible, functional insulin treatment: assessment of improvements in treatment satisfaction with a new insulin analogue. Qual Life Res 9:915-930, 2000Medline
15.DAFNE Study Group. Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomized controlled trial. BMJ 325:746, 2002Abstract/FREE Full Text
16.Bradley C, Todd C, Gorton T, Symonds E, Martin A, Plowright R: The development of an individualized questionnaire measure of perceived impact of diabetes on quality of life: the ADDQoL. Qual Life Res 8:79-91, 1999CrossRefMedlineWeb of Science
17.Bradley C, Speight J: Patient perceptions of diabetes and diabetes therapy. Diabetes Metab Res Rev 18(Suppl. 3):S64-S69, 2002CrossRefMedlineWeb of Science
18.Bradley C, Lewis K: Measures of psychological well-being and treatment satisfaction developed from the responses of people with tablet-treated diabetes. Diabet Med 7:445-451, 1990MedlineWeb of Science
19.Bradley C: The Diabetes Treatment Satisfaction Questionnaire. In Handbook of Psychology and Diabetes: A Guide to Psychological Measurement in Diabetes Research and Practice. Bradley C, Ed. Chur, Switzerland, Harwood Academic Publishers, 1994, p. 111-132
20.Bradley C: Diabetes treatment satisfaction questionnaire: change version for use alongside status version provides appropriate solution where ceiling effects occur. Diabetes Care 22:530-532, 1999CrossRefMedlineWeb of Science
21.Bradley C, Witthaus E, Stewart J: Treatment satisfaction and psychological well-being in patients with type 1 diabetes treated with a new long-acting insulin glargine. Diabetes 48:A353, 1998
22.Tamas G, Marre M, Astorga R, Dedov I, Jacobsen J, Lindholm A: Glycaemic control in type 1 diabetic patients using optimised insulin aspart or human insulin. Diabetes Res Clin Pract 54:105-114, 2001CrossRefMedlineWeb of Science
23.Bradley C: Psychological issues in clinical trial design. Ir J Psychol 18:67-87, 1997